Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry
2000; Wiley; Volume: 88; Issue: 4 Linguagem: Inglês
10.1002/(sici)1097-0142(20000215)88
ISSN1097-0142
AutoresPeter Duggan, David Easton, Joanne Luider, Iwona Auer,
Tópico(s)Viral-associated cancers and disorders
ResumoImmunophenotypic analysis is an established tool in the diagnosis and classification of many hematolymphoid disorders; however, the role of flow cytometry (FC) in detecting bone marrow involvement during the staging of non-Hodgkin lymphoma (NHL) has yet to be defined.The authors retrospectively analyzed 157 staging and 70 restaging bone marrow biopsies on which morphologic and FC analyses were performed; these biopsies were taken from 195 consecutive patients. Bone marrow biopsies were blindly and independently reviewed and determined to be positive, negative, or suspicious for morphologic involvement by NHL, with disagreements settled by a third reviewer. A selected panel of monoclonal antibodies was used to determine whether bone marrow involvement was immunophenotypically positive (>5%), minimal ( 5%. Cases of early stage NHL with morphologically negative bone marrow could potentially be restaged as Stage IV on the basis of FC results. The clinical importance of minimal bone marrow involvement by NHL needs further evaluation.
Referência(s)